loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Emcure Pharmaceuticals has expanded the indication of its co-marketed brand Poviztra

ICICIdirect Research 21 Jul 2026 DISCLAIMER

News: Emcure Pharmaceuticals has expanded the indication of its co-marketed brand Poviztra (innovator semaglutide) following CDSCO's approval of semaglutide for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis (F2-F3). The approval makes semaglutide the first and only GLP-1 receptor agonist approved in India for MASH. Manufactured and imported from Novo Nordisk's European facility, Poviztra will be commercialised through Zuventus Healthcare's gastroenterology and hepatology portfolio to expand disease awareness, diagnosis and patient access. 

View: This development for Emcure is followed by the approval received by Novo Nordisk's Wegovy for MASH indication. This will help Emcure to reach further more specialists which was earlier limited to endocrinologists and diabetologists.

Impact: Positive

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere